Based on the earnings transcript, Amgen showed generally positive performance with some mixed signals. Key positives include strong performance of core products like Enbrel and Filgrastim, successful launches of new products XGEVA and Prolia, and reaffirmed full-year guidance. The company also demonstrated financial discipline and strategic investments in R&D and commercialization. However, there were some headwinds including increased operating expenses and declines in EPOGEN/Aranesp sales. Overall, the management's confident tone, strong product launches, and maintained guidance suggest a positive short-term outlook, though tempered by some cost pressures.

[1]